Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda

Dolutegravir (DTG) is now a preferred component of first-line antiretroviral therapy (ART). However, prevalence data on natural resistance to integrase inhibitors [integrase strand transfer inhibitors (INSTIs)] in circulating non-subtype B HIV-1 in sub-Saharan Africa is scarce. Our objective is to r...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	AIDS (London) 2021-06, Vol.35 (7), p.1083-1089
Hauptverfasser:	McCluskey, Suzanne M., Kamelian, Kimia, Musinguzi, Nicholas, Kigozi, Simone, Boum, Yap, Bwana, Mwebesa B., Muzoora, Conrad, Brumme, Zabrina L., Carrington, Mary, Carlson, Jonathan, Foley, Brian, Hunt, Peter W., Martin, Jeffrey N., Bangsberg, David R., Harrigan, P. Richard, Siedner, Mark J., Haberer, Jessica E., Lee, Guinevere Q.
Format:	Artikel
Sprache:	eng
Schlagworte:	Africa South of the Sahara Drug Resistance, Viral - genetics HIV Infections - drug therapy HIV Integrase - genetics HIV Integrase Inhibitors - pharmacology HIV Integrase Inhibitors - therapeutic use HIV-1 - genetics Humans Mutation Retrospective Studies Uganda
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!